Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010

23 Jan 2008

• By Jessica Merrill

Firm expects data from pivotal 24-week trials in mid-2010.

Related Content

Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race

18 Oct 2007

Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program

02 Feb 2007

Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course

16 Apr 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.